Recent guidelines of using SGLT 2 inhibitiors
Reading File
Searching PubMed
SGLT2 inhibitors guidelines recommendations
Searching the Web
SGLT2 inhibitors guidelines 2024 2025 recommendations heart failure CKD diabetes
Finding Sources
Reading Article
Reading Article
Reading File
Finding Sources
Reading Article
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile the full answer.
SGLT2 Inhibitors: Recent Guidelines (2024-2026)
SGLT2 inhibitors (gliflozins) have undergone a dramatic expansion in their recommended indications over the past few years. They are no longer simply diabetes drugs - they are now considered foundational cardiorenal-metabolic therapy.
Available Agents & Doses
| Drug | Doses Available | Key Indications |
|---|---|---|
| Dapagliflozin (Farxiga) | 5 mg, 10 mg | T2DM, HFrEF, HFpEF (LVEF >40%), CKD |
| Empagliflozin (Jardiance) | 10 mg, 25 mg | T2DM, HFrEF, HFpEF, CKD |
| Canagliflozin (Invokana) | 100 mg, 300 mg | T2DM, CKD, CV risk reduction |
| Ertugliflozin (Steglatro) | 5 mg, 15 mg | T2DM |
All are once-daily oral agents with ~60-80% bioavailability, unaffected by food. Half-life ~12 hours. Metabolized by glucuronidation; inactive metabolites renally excreted.
1. Type 2 Diabetes (T2DM)
ACP 2024 Guideline (Ann Intern Med, 2024 - PMID 38639546):
- Strong recommendation (high-certainty evidence): Add an SGLT2 inhibitor or GLP-1 agonist to metformin + lifestyle modification when glycemic targets are not met.
- SGLT2 inhibitors are specifically preferred to:
- Reduce all-cause mortality
- Reduce major adverse cardiovascular events (MACE)
- Slow CKD progression
- Reduce hospitalization for heart failure
- DPP-4 inhibitors are recommended against as second-line agents for morbidity/mortality reduction.
ADA Standards of Care (ongoing):
- SGLT2 inhibitors recommended as preferred add-on for patients with T2DM and established ASCVD, HF, or CKD - regardless of HbA1c level.
- Use an SGLT2i with eGFR ≥20 mL/min/1.73 m² + uACR ≥300 mg/g to reduce CKD progression and CV events.
2. Heart Failure (HF)
Guidelines from both US (ACC/AHA) and Europe (ESC) now recommend SGLT2 inhibitors as foundational therapy regardless of ejection fraction or diabetes status - Harrison's Principles of Internal Medicine, 22nd Ed.
HFrEF (LVEF ≤40%)
- Dapagliflozin and empagliflozin: Both are Class I recommendations added to optimal background therapy (ACEi/ARNI + beta-blocker + MRA).
- Key trials: DAPA-HF (dapagliflozin) and EMPEROR-REDUCED (empagliflozin) - both showed reduced CV mortality and HF hospitalization in patients with and without diabetes.
HFpEF / HFmEF (LVEF >40%)
- SGLT2 inhibitors are now endorsed as the only class with clear mortality and morbidity benefit in HFpEF.
- EMPEROR-Preserved trial: empagliflozin reduced CV death or HF hospitalization by 21% (HR 0.79; 95% CI 0.69-0.90) and recurrent HF hospitalizations by 27%, with no modification by diabetes status.
- DELIVER trial: dapagliflozin confirmed similar benefits in LVEF >40%.
- Practical note: SGLT2 inhibitors may allow titration/reduction of loop diuretics due to their natriuretic effect. - Fuster and Hurst's The Heart, 15th Ed.
Practical HF Initiation Tips
- In patients on sulfonylureas or insulin with well-controlled diabetes: reduce/stop diuretic or sulfonylurea/insulin dose before starting SGLT2i to avoid hypovolemia/hypoglycemia.
- If hypervolemic or poorly controlled: no pre-adjustment needed. - Lippincott Illustrated Reviews Pharmacology
3. Chronic Kidney Disease (CKD)
KDIGO 2024 Clinical Practice Guideline (Ann Intern Med, 2025 - PMID 40063957):
| CKD Stage | eGFR | Canagliflozin | Dapagliflozin |
|---|---|---|---|
| Stage 3a | 45-59 | 100-300 mg/day | 10 mg/day |
| Stage 3b | 30-44 | 100 mg/day (max) | 10 mg/day |
| Stage 4 | 15-29 | Do not initiate; continue 100 mg if tolerated | 10 mg/day |
| Stage 5 / Dialysis | <15 | Generally avoid initiation | Generally avoid |
Key KDIGO 2024 recommendations:
- Treat CKD patients with T2DM and eGFR ≥20 mL/min/1.73 m² with an SGLT2 inhibitor (Grade 1A).
- Benefits extend to non-diabetic CKD - DAPA-CKD trial showed consistent reduction in CKD progression and death regardless of diabetes status, including patients with chronic glomerulonephritides. - Comprehensive Clinical Nephrology, 7th Ed.
- Note: Glycemic efficacy is reduced as eGFR falls, but renal and cardiovascular protective effects are preserved down to eGFR 20-25 mL/min/1.73 m².
Key trials driving CKD recommendations:
- CREDENCE: Canagliflozin in T2DM + CKD (eGFR 30-90) - reduced kidney failure, death from kidney/CV causes.
- DAPA-CKD: Dapagliflozin in CKD with and without T2DM - significant reduction in eGFR decline, ESKD, and mortality.
- EMPA-KIDNEY: Empagliflozin in CKD eGFR 20-45 with uACR ≥200 - confirmed renoprotective benefits.
4. Perioperative Management (2025 Consensus)
PMID 39781571 (Anaesthesia, 2025 - multidisciplinary UK consensus):
- SGLT2 inhibitors should generally be withheld 3-4 days before elective surgery due to risk of euglycemic DKA.
- Resume when patient is eating and drinking normally and surgical stress has resolved.
5. Combined SGLT2i + GLP-1RA Use
Lancet Diabetes Endocrinol, 2024 (SMART-C meta-analysis - PMID 38991584):
- SGLT2 inhibitors provide independent, additive cardiovascular and kidney benefits even when combined with GLP-1 receptor agonists.
- Effects on MACE (HR ~0.90), HF hospitalization/CV death (HR ~0.78), and CKD progression (HR ~0.67) were consistent regardless of background GLP-1RA use.
- This supports combination use of both drug classes per current guidelines.
Adverse Effects & Contraindications
| Effect | Notes |
|---|---|
| Genital mycotic infections | 3-5% increase; most common in women |
| Urinary tract infections | ~2% increase |
| Volume depletion / hypotension | Especially in elderly; monitor diuretics |
| Euglycemic DKA | Rare but serious; risk with illness, fasting, surgery - withhold perioperatively |
| Fournier gangrene | Rare necrotizing fasciitis of perineum |
| Initial eGFR dip | Transient, functional; resolves; does NOT indicate harm |
| Hypoglycemia | Not from SGLT2i alone; risk increases with concurrent sulfonylurea/insulin |
| Bone fractures | Early canagliflozin signals not confirmed in further studies |
Contraindications: eGFR <20-25 mL/min/1.73 m² (for initiation), recurrent UTIs, T1DM (relative), pregnancy and breastfeeding (avoid - insufficient safety data). - Goodman & Gilman's Pharmacological Basis of Therapeutics
Summary of Guideline-Endorsed Indications
| Indication | Agent(s) | Diabetes Required? |
|---|---|---|
| T2DM + inadequate glycemic control | Any SGLT2i | Yes |
| T2DM + ASCVD/high CV risk | Empagliflozin, canagliflozin, dapagliflozin | Yes |
| HFrEF (any EF ≤40%) | Dapagliflozin, empagliflozin | No |
| HFpEF/HFmEF (EF >40%) | Empagliflozin, dapagliflozin | No |
| CKD (eGFR ≥20, uACR ≥200-300) | Dapagliflozin, canagliflozin, empagliflozin | No |
Key principle: The cardiorenal benefits of SGLT2 inhibitors are largely independent of glucose lowering - they work through hemodynamic, tubuloglomerular feedback, and possibly mitochondrial/NHE-inhibition mechanisms. This is why benefits extend to non-diabetic patients.
Sources: Harrison's Principles of Internal Medicine 22E (2025); Fuster and Hurst's The Heart, 15th Ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics; Comprehensive Clinical Nephrology 7th Ed.; ACP 2024 Guideline (PMID 38639546); KDIGO 2024 CKD Guideline Synopsis (PMID 40063957); SMART-C Meta-Analysis, Lancet Diabetes Endocrinol 2024 (PMID 38991584); Perioperative Consensus, Anaesthesia 2025 (PMID 39781571)
This is a shared conversation. Sign in to Orris to start your own chat.